KING OF PRUSSIA, Pa., June 13, 2018 /PRNewswire/ -- Greenphire, the global leader in financial software for clinical trials, today announced enhancements to its eClinicalGPS site payment solution, expanding configuration and administration options, providing CROs and sponsors unmatched capability, flexibility, and control. With these enhancements, Greenphire is positioned to take an even more collaborative and strategic role with CRO and sponsor partners in identifying the delivery model, whether self-service, full service, or somewhere in between, to maximize the ROI in site payment automation.
Increasing trial complexity and expanding industry emphasis on site centricity are contributing to the rapid evolution of grant payment management. The latest enhancements to Greenphire's SaaS-based eClinicalGPS make it possible for more sponsors and CROs to automate their investigator payment processes globally.
"A one-size-fits-all approach to site payments is not scalable or sustainable in today's clinical research landscape," said Jim Murphy, CEO of Greenphire. "Sponsors and CROs focused on optimizing payment processes need advanced financial features which can be configured to support their unique workflows, as well as those of their investigative sites around the world."
Among the new features and functionality supporting greater sponsor and CRO payment flexibility are:
eClinicalGPS is the site payment software of choice for global sponsors and CROs looking to automate investigator grant payments enterprise-wide. Backed by a team of experts in global financial software development for clinical research that delivers measurable ROI, the SaaS-based solution leads the industry in technology sophistication and adoption around the world.
For more information, or to schedule a demo, contact sales@greenphire.com.
About Greenphire
Greenphire is the global leader in clinical trial payment automation. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials. Learn more at www.greenphire.com.
Media Contact:
Kathleen Fusco
(267) 828-4862
Kathleen.Fusco@greenphire.com
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.